Long-term buprenorphine-naloxone	Short-term buprenorphine-naloxone	HCV infection	11398	11539	Overall, in China, short-term versus long-term B-N treatment was not associated with HCV infection (HR = 0.95; 95% CI, 0.45 to 1.97; P = 0.9)
Long-term buprenorphine-naloxone	Short-term buprenorphine-naloxone	HCV infection	11398	11602	Overall, in China, short-term versus long-term B-N treatment was not associated with HCV infection (HR = 0.95; 95% CI, 0.45 to 1.97; P = 0.9) with the Kaplan Meier curve shown in Figure 1 by treatment arm
Long-term buprenorphine-naloxone	Short-term buprenorphine-naloxone	HB surface antigen 	9486	9670	the incidence of becoming HBsAg positive in the short- versus long-term B-N treatment was 4.34/100 person years versus 1.15/100 person years (HR = 3.55; 95% CI 0.74 to 17.08, P = 0.11)
Long-term buprenorphine-naloxone	Short-term buprenorphine-naloxone	HB surface antigen 	9467	9670	In PWIDs in China, the incidence of becoming HBsAg positive in the short- versus long-term B-N treatment was 4.34/100 person years versus 1.15/100 person years (HR = 3.55; 95% CI 0.74 to 17.08, P = 0.11)
